ODYSSEY trial
Study / Research
A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.
Mentioned in 2 videos
Videos Mentioning ODYSSEY trial
Cardiovascular disease & why we should change the way we assess risk | The Peter Attia Drive Podcast
Peter Attia MD
A clinical trial similar to the FOURIER trial, which likely showed a greater risk reduction due to patients starting at higher LDL-C levels.
230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more
Peter Attia MD
A cardiovascular outcome trial for Alirocumab (a PCSK9 inhibitor) in patients with recent acute coronary syndrome, showing a 15% reduction in major adverse cardiovascular events.